Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) EBT Margin (2019 - 2023)

Benitec Biopharma has reported EBT Margin over the past 5 years, most recently at 65114.29% for Q2 2023.

  • Quarterly results put EBT Margin at 65114.29% for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was 307371.43% (down 27898319.0% YoY), and the annual figure for FY2023 was 25485.33%, down 98396.0%.
  • EBT Margin reached 65114.29% in Q2 2023 per BNTC's latest filing, down from 8051.85% in the prior quarter.
  • Across five years, EBT Margin topped out at 8220.0% in Q2 2020 and bottomed at 379500.0% in Q1 2021.
  • Median EBT Margin over the past 5 years was 8051.85% (2023), compared with a mean of 80666.78%.
  • The largest annual shift saw EBT Margin tumbled -37201786bps in 2021 before it surged 37227083bps in 2022.
  • Over 5 years, EBT Margin stood at 2719.48% in 2019, then crashed by -11891bps to 326100.0% in 2020, then surged by 94bps to 19384.0% in 2021, then crashed by -107bps to 40135.71% in 2022, then plummeted by -62bps to 65114.29% in 2023.
  • Business Quant data shows EBT Margin for BNTC at 65114.29% in Q2 2023, 8051.85% in Q1 2023, and 40135.71% in Q4 2022.